Study of NXT007 vs emicizumab for hemophilia A
Treatments studied
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This trial tests if a new medicine, NXT007, is better than emicizumab at preventing bleeding episodes in people with hemophilia A. It may be an option for those with or without inhibitors who are willing to switch to a preventive treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have severe or moderate hemophilia A (with or without inhibitors), or mild hemophilia A with chronic inhibitors that lower your factor VIII levels.
- You have records of your past bleeding episodes and treatments for at least 6 months.
- If you currently use on-demand treatment, you agree to switch to a preventive treatment (emicizumab or NXT007).
- You do not have a known allergy to study drugs or their ingredients.
- You are not using certain immune-suppressing medications, like interferon or rituximab.
- You have no history of serious heart rhythm problems or heart disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called NXT007 for people with hemophilia A. It compares NXT007 to standard factor VIII treatment to see if it works better at preventing bleeding episodes.
This study tests a new medicine called NXT007 for people with moderate or severe hemophilia A. The goal is to see if it is safe, well-tolerated, and can help prevent or reduce bleeding episodes, possibly reducing the need for standard treatments. You may be able to join if you have hemophilia A with or without inhibitors and meet other health requirements.
This study tests a new preventive treatment (NXT007) to help stop bleeding episodes in infants and children with hemophilia A. It aims to see if this treatment reduces the number of bleeds and improves quality of life.
This trial compares two low-dose medicines to prevent bleeding episodes in people with severe hemophilia A: a newer medicine (emicizumab) versus the standard factor VIII treatment. It may help find a more convenient or effective way to reduce bleeding.
This trial studies a treatment approach for people with hemophilia A who develop antibodies (inhibitors) that block clotting factor FVIII. It may help those whose usual FVIII therapy is not working because of these inhibitors.
This study looks at whether aPCC (a clotting medicine) is safe to use for bleeding safety in people with hemophilia A who are already taking emicizumab. It mainly checks side effects and safety after switching to or using aPCC when needed.
Hear when a new Hemophilia A trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.